How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,216 results for

Myocardial Infarction Stabilization

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Myocardial Perfusion Imaging

contraindications to dynamic exercise The following are generally considered to be absolute contraindications to exercise stress, though under some circumstances exercise may be clinically appropriate under experienced medical supervision: ? ST-segment elevation myocardial infarction within the previous 4 days ? non-ST-segment elevation acute coronary syndrome. Once stabilised, exercise stress can be considered 24 to 72 hours after chest pain depending upon clinically assessed risk.[40] ? left main coronary (...) to vasodilator stress ? Unstable acute coronary syndrome. Adenosine stress can be performed early (24-48 hours) after an uncomplicated acute infarction ? suspected or known severe bronchospasm, although regadenoson can be used in selected patients ? second and third degree atrioventricular block in the absence of a functioning pacemaker ? sick sinus syndrome in the absence of a functioning pacemaker ? hypotension (SBP 50% of maximum myocardial uptake),[66]significant tracer uptake outside the heart

2012 British Nuclear Medicine Society

182. Dynamic Changes in SDF-1α Levels in Acute and Stabilized Heart Disease

in Stromal Cell-derived Factor-1α Levels in Acute and Stabilized Heart Disease - ACUTE MYOCARDIAL INFARCTION, ATRIAL FIBRILLATION, AND HEART FAILURE (THE DYNASDY STUDY) Study Start Date : November 2015 Actual Primary Completion Date : December 2016 Estimated Study Completion Date : December 2017 Resource links provided by the National Library of Medicine related topics: related topics: Arms and Interventions Go to Arm Intervention/treatment DYNASDY The study considers changes in SDF-1α levels in response (...) to treatment of cardiac disease (myocardial infarction, heart failure or atrial fibrillation). SDF-1α levels will be measured at the acute stages of the disease, after stabilization and at longer term as detailed below. Levels of SDF-1α will be correlated to the outcome of disease. Other: DYNASDY Measurement of SDF-1 alpha levels i patients' blood samples. Active Comparator: Control group A control group of 20 subjects without cardiac disease (including hypertension), diabetes, hypercholesterolemia

2015 Clinical Trials

183. Stabilization of Fresh Unilateral Unstable Pertrochanteric Hip Fracture

to complete the study assessment and visit schedule in the opinion of the investigating team Exclusion Criteria: Unable to ambulate pre-injury, even with walking aids Unable to undergo surgical fixation within 7 days of admission Patient is for any reason considered unable to carry out the required study assessments or complete the follow-up visit schedule, in the opinion of the investigating team Previous stroke (non-recovered) Recent myocardial infarction (up to 60 days) Presence of fracture(s (...) Stabilization of Fresh Unilateral Unstable Pertrochanteric Hip Fracture Stabilization of Fresh Unilateral Unstable Pertrochanteric Hip Fracture - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Stabilization

2015 Clinical Trials

184. Hemodynamic Stability During Pheochromocytoma Resection: Lessons Learned Over the Last Two Decades. (PubMed)

, and perioperative management were examined. Postoperative intensive-care admission, myocardial infarction, stroke, and 30-day mortality were reviewed. Linear regression was used to analyze factors influencing intraoperative hemodynamics.During the 20-year study period, 100 patients underwent pheo resection. Postoperative morbidity and mortality was significantly reduced (p = 0.003) in the last 10 years of practice, and there was a trend towards greater morbidity and mortality with intraoperative hemodynamic (...) Hemodynamic Stability During Pheochromocytoma Resection: Lessons Learned Over the Last Two Decades. Ideal perioperative management of pheochromocytomas/paragangliomas (pheo) is a subject of debate and can be highly variable. The purpose of this study was to identify potential predictive factors of hemodynamic instability during pheo resection.A retrospective review of pheo resections from 1992 to 2013 was undertaken. Intraoperative hemodynamics, patient demographics, tumor characteristics

2015 Annals of Surgical Oncology

185. Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Gastric Inflammation Patients

thrombosis, myocardial infarction, septic thrombophlebitis) and who have antithrombotic agents (eg. warfarin) Contacts and Locations Go to No Contacts or Locations Provided More Information Go to Layout table for additonal information Responsible Party: Daewon Pharmaceutical Co., Ltd. ClinicalTrials.gov Identifier: Other Study ID Numbers: DW 3101_201 First Posted: March 11, 2015 Last Update Posted: October 12, 2016 Last Verified: October 2016 Additional relevant MeSH terms: Layout table for MeSH terms (...) Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Gastric Inflammation Patients Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Gastric Inflammation Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2015 Clinical Trials

186. Plaque Stabilization and Restoration by Bioresorbable Vascular Scaffold

stenosis in the target vessel. Left main (>50%) or known three vessel disease. Patients presenting with acute myocardial infarction, unstable arrhythmias, or patients who have a left ventricular ejection fraction <30% Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparine or Everolimus and known true anaphylaxis to prior contrast media or known bleeding diathesis or known coagulopathy. Planned elective surgical procedure necessitating interruption of dual antiplatelet therapy during (...) Plaque Stabilization and Restoration by Bioresorbable Vascular Scaffold Plaque Stabilization and Restoration by Bioresorbable Vascular Scaffold - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Plaque

2014 Clinical Trials

187. Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis

Informed written consent Exclusion Criteria: Patients under particular protection Enrolment in another biomedical research in the last 3 months; Patients for whom physical practice is contra-indicated because of : Unstable coronary Syndrome or myocardial infarction within the past 3 months Heart failure with systolic ejection fraction < 50 % Respiratory failure defined by a vital capacity (CV) < 70 % Stroke Other neuromuscular pathology Disabling Rheumatologic disease (> 80 % disability according (...) Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2014 Clinical Trials

188. Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer

: myocardial infarction (MI), severe/unstable angina, coronary artery bypass graft (CABG), congestive heart failure (CHF), cerebrovascular accident (CVA), transient ischemic attack (TIA), pulmonary embolism (PE) Uncontrolled hypertension defined by a systolic blood pressure (SBP) >= 160 mmHg and/or diastolic blood pressure (DBP) >= 100 mm Hg, with or without anti-hypertensive medication Previous pericarditis; clinically significant pleural effusion in the previous 12 months or current ascites requiring two (...) Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information

2014 Clinical Trials

189. Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer

) of New York Heart Association (NYHA) class >= 3, or Myocardial infarction (MI) within 3 months of cycle 1 day 1 dose Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose Known to be HIV seropositive who are on anti-HIV drugs because of the unknown interactions between these drugs and the study agents Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus (HCV) ribonucleic acid (RNA) or HBsAg (...) Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved

2014 Clinical Trials

190. Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

procedure during the course of the study Other medical conditions including but not limited to: History of liver disease such as cirrhosis, chronic active hepatitis, chronic persistent hepatitis or hepatitis B or C Active infection requiring parenteral antibiotics Poorly controlled high blood pressure (>= 150 mmHg systolic and/or 100 mmHg diastolic) despite treatment New York Heart Association class II-IV congestive heart failure Serious cardiac arrhythmia requiring medication Myocardial infarction (...) Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x

2014 Clinical Trials

191. Low-expression variant of fatty acid-binding protein 4 favors reduced manifestations of atherosclerotic disease and increased plaque stability. (PubMed)

the effects of this low-expression variant of FABP4 on cardiovascular morbidity and carotid atherosclerosis on a population level (n=7491) and in patient cohorts representing endarterectomized patients with advanced carotid atherosclerosis (n=92) and myocardial infarction (n=3432). We found that the low-expression variant was associated with decreased total cholesterol levels (P=0.006) with the largest reduction in variant allele homozygotes. Obese variant allele carriers also showed reduced carotid (...) intima-media thickness (P=0.010) and lower prevalence of carotid plaques (P=0.060). Consistently, the variant allele homozygotes showed 8-fold lower odds for myocardial infarction (P=0.019; odds ratio, 0.12; 95% confidence interval, 0.003-0.801). Within the carotid plaques, the variant allele was associated with a 3.8-fold reduction in FABP4 transcription (P=0.049) and 2.7-fold reduction in apoptosis (activated caspase 3; P=0.043). Furthermore, the variant allele was enriched to patients

Full Text available with Trip Pro

2014 Circulation. Cardiovascular genetics

192. Functional Stability of Plasminogen Activator Inhibitor-1 (PubMed)

Functional Stability of Plasminogen Activator Inhibitor-1 Plasminogen activator inhibitor-1 (PAI-1) is the main inhibitor of plasminogen activators, such as tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), and a major regulator of the fibrinolytic system. PAI-1 plays a pivotal role in acute thrombotic events such as deep vein thrombosis (DVT) and myocardial infarction (MI). The biological effects of PAI-1 extend far beyond thrombosis including its (...) function may be misleading in interpreting the role of PAI-1 in many complex diseases. Environmental conditions, interaction with other proteins, mutations, and glycosylation are the main factors that have a significant impact on the stability of the PAI-1 structure. This review provides an overview on the current knowledge on PAI-1 especially importance of PAI-1 level and stability and highlights the potential use of PAI-1 inhibitors for treating cardiovascular disease.

Full Text available with Trip Pro

2014 The Scientific World Journal

193. [Percutaneous coronary intervention in addition to optimal medical therapy for stabile coronary artery disease - A systematic review and meta-analysis]. (PubMed)

trials (RCT) and systematic reviews of RCT comparing PCI vs. no PCI in stable CAD  were identified and evaluated. Results for death, myocardial infarction and angina pectoris of the RCTs using optimal medical therapy were combined with meta-analysis for relative risk (RR). The strength of the evidence was appraised based on GRADE.After evaluation of 7 systematic reviews and 23 RCT 4 RCTs using optimal medical therapy (Betablockers, ASS, Statins in more than 80% and ACE-Inhibitors in more than 50 (...) % of patients the study) were identified. No significant difference was found for the risks of death and of myocardial infarction between the alternatives up to 5 years after beginning the therapy. The PCI reduced the proportion of patients with angina pectoris attacks up to 3 years after beginning the therapy, RR = 0,81 (95 % CI: 0,71 to 0,92). The strength of the evidence was appraised as moderate.The use of PCI in addition to optimal medical therapy in stable CAD  may reduce the proportion of patients

2014 Deutsche medizinische Wochenschrift (1946)

194. Fractional Flow Reserve (FFR) Stability in Non-Culprit Vessels at ST Elevation Myocardial Infarction(STEMI)

Fractional Flow Reserve (FFR) Stability in Non-Culprit Vessels at ST Elevation Myocardial Infarction(STEMI) Fractional Flow Reserve (FFR) Stability in Non-Culprit Vessels at ST Elevation Myocardial Infarction(STEMI) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Fractional Flow Reserve (FFR) Stability in Non-Culprit Vessels at ST Elevation Myocardial Infarction(STEMI) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01065103 Recruitment Status : Completed First Posted : February 9, 2010 Last Update

2010 Clinical Trials

195. Acute Myocardial Necrosis and Depression: Antiplatelet Effect of Reuptake Inhibition of Serotonin

2016 Keywords provided by Assistance Publique - Hôpitaux de Paris: Acute Coronary Syndrome Depression Coronary Artery Disease Myocardial Infarction Percutaneous Coronary Intervention Additional relevant MeSH terms: Layout table for MeSH terms Depression Depressive Disorder Coronary Artery Disease Myocardial Ischemia Coronary Disease Necrosis Myocardial Infarction Behavioral Symptoms Mood Disorders Mental Disorders Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases (...) Acute Myocardial Necrosis and Depression: Antiplatelet Effect of Reuptake Inhibition of Serotonin Acute Myocardial Necrosis and Depression: Antiplatelet Effect of Reuptake Inhibition of Serotonin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove

2015 Clinical Trials

196. Febuxostat pretreatment attenuates myocardial ischemia/reperfusion injury via mitochondrial apoptosis (PubMed)

h before exposure to hypoxia for 3 h followed by reoxygenation for 3 h. Cardiac function, myocardial infarct size, serum levels of creatine kinase (CK) and lactate dehydrogenase (LDH), and myocardial apoptotic index (AI) were measured in order to ascertain the effects of febuxostat on myocardial I/R injury. Hypoxia/reperfusion (H/R) injury in NRCs was examined using MTT, LDH leakage assay and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. The underlying mechanisms (...) were determined by measuring ROS production, mitochondrial membrane potential (ΔΨm), and expression of cytochrome c, cleaved caspases as well as Bcl-2 protein levels.Myocardial I/R led to an elevation in the myocardial infarct size, serum levels of CK and LDH, cell death and AI. Furthermore, I/R reduced cardiac function. These changes were significantly attenuated by pretreatment with febuxostat and allopurinol, especially by febuxostat. Febuxostat also protected the mitochondrial structure

Full Text available with Trip Pro

2015 Journal of translational medicine

197. Shuangshen Ningxin Capsule, a Traditional Chinese Medicinal Preparation, Alleviates Myocardial Ischemia through Autophagy Regulation. (PubMed)

Shuangshen Ningxin Capsule, a Traditional Chinese Medicinal Preparation, Alleviates Myocardial Ischemia through Autophagy Regulation. Shuangshen Ningxin capsule (SSNX), a modern Chinese formula, has been used to treat cardiovascular diseases in Eastern Asia. Our study focuses on the autophagy regulation of SSNX against coronary artery injuries. Myocardial infarction model was established in Chinese miniswines (CMS) by coronary artery balloon injury. SSNX was administered to the CMS for 8 weeks (...) expressions by Western blot. The results showed that CMS treated with SSNX exhibited the correction for the disturbed cardiac hemodynamics, increase of coronary artery diameter, reduction of high plaque burden and plaque volume, and decrease of LDH. The inhibitory effect of SSNX on CMS autophagy was demonstrated by the reduction of autophagosome and the downregulation of beclin-1 and LC3-I/II. SSNX may protect coronary artery and increase the stability of plaque through the suppression of myocardial

Full Text available with Trip Pro

2015 Evidence-based Complementary and Alternative Medicine (eCAM)

198. Rosuvastatin for Reduction of Myocardial Damage and Systemic Inflammation During Coronary Angioplasty

, Layout table for eligibility information Ages Eligible for Study: Child, Adult, Older Adult Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: - suspected CAD for which an indication to PCI is given: both patients with stable CAD, and stable post-acute coronary syndromes (ACS), both with ST-segment elevation (STEMI) and without ST-segment elevation (NSTE-ACS) patients, provided that markers of myocardial necrosis (CK-MB, troponins) are stabilized (i.e (...) ., with variations <20% in two consecutive measurements obtained at ≥6 h time distance before PCI, according to the universal definition of peri-procedural myocardial infarction). Exclusion Criteria: any previously known increase in liver enzymes (AST, ALT) ascribed to liver dysfunction at baseline; history of liver toxicity or myopathy on previous treatment with statins; left ventricular ejection fraction <30%; renal insufficiency, with creatinine >2 mg/dL at baseline; ongoing treatment with high-dose statins

2014 Clinical Trials

199. Safety & Efficacy of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia (ATHENA II)

A high-risk acute coronary syndrome (ACS) or a myocardial infarction in the 60 days prior to randomization Revascularization within 60 days prior to randomization Inability to walk on a treadmill except for class IV angina patients who will be evaluated separately Hepatic dysfunction, as defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 1.5 times the upper limit of normal range (x ULN) Hemoglobin ≤ 10.0 g/dL Contacts and Locations Go to Information from the National (...) Safety & Efficacy of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia (ATHENA II) Safety & Efficacy of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia (ATHENA II) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2014 Clinical Trials

200. Myocardial Rupture (Treatment)

of free-wall rupture while patients are being transferred to the OR. Previous Next: Surgical Repair In most patients, immediate surgery is necessary and should not be delayed by attempts to stabilize the patient medically. Papillary muscle rupture is generally treated with mitral valve replacement. Free-wall rupture is treated by resecting the infarcted area and closing the rupture zone with Teflon or Dacron patches or by using of biologic glues. Successful off-pump surgery (without the use (...) , Lick S, Uretsky BF. Contained myocardial rupture: a variant linking complete and incomplete rupture. Heart . 2005 Feb. 91(2):e13. . Okino S, Nishiyama K, Ando K, Nobuyoshi M. Thrombolysis increases the risk of free wall rupture in patients with acute myocardial infarction undergoing percutaneous coronary intervention. J Interv Cardiol . 2005 Jun. 18(3):167-72. . Kumar S, Kaushik S, Nautiyal A, et al. Cardiac rupture in takotsubo cardiomyopathy: a systematic review. Clin Cardiol . 2011 Nov. 34(11

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>